IceCure Medical Ltd (ICCM)
| Market Cap | 4.68M -91.4% |
| Revenue (ttm) | 3.95M +41.6% |
| Net Income | -16.88M |
| EPS | -6.66 |
| Shares Out | 4.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,353 |
| Open | 1.020 |
| Previous Close | 1.000 |
| Day's Range | 1.010 - 1.070 |
| 52-Week Range | 0.960 - 24.900 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 22.67 (+2,144.55%) |
| Est. Earnings | Nov 18, 2026 |
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncolo... [Read more]
Financial Performance
In 2025, IceCure Medical's revenue was $3.38 million, an increase of 2.67% compared to the previous year's $3.29 million. Losses were -$15.06 million, -1.70% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price target is $22.67, which is an increase of 2,144.55% from the latest price.
News
IceCure Medical begins enrollment in ProSense breast cancer cryoablation study
Medical announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study evaluating ProSense cryoablation for the local treatment of low-risk breast cancer. Th...
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
Scientific presentations, research posters and clinical workshops featured ProSense® breast cancer cryoablation and highlighted strong physician engagement across Europe CAESAREA, Israel, October 13, ...
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroy...
IceCure Medical management to meet with Lake Street
Meeting to be held in New York on October 7 hosted by Lake Street.
IceCure Medical granted regulatory approval to market ProSense in China
IceCure Medical (ICCM) has received approval, as a Class III medical device, from China’s National Medical Products Administration for its ProSense system and associated cryoprobes. The NMPA approval ...
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd.
IceCure Medical announces distribution agreement with Scovas Medical
IceCure Medical (ICCM) announced that it has entered into an exclusive distribution agreement with Scovas Medical for the distribution of IceCure’s ProSense cryoablation systems in the Netherlands for...
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the...
IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center
IceCure Medical (ICCM) announced that the Institutional Review Board of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the company’s post-marketing study fo...
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAE...
IceCure Medical highlights two publications supporting ProSense’s cryoablation
IceCure Medical (ICCM) highlighted two recent peer-reviewed publications by U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation. A new review...
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical t...
IceCure Medical Earnings Call Transcript: Q2 2026
Revenue grew 45% year-over-year to $1.8M, driven by increased physician adoption and a 70% rise in the U.S. install base. Gross margin improved to 30%, and cash reserves reached $12M after new financing. The ChoICE Study and international expansion continue to support long-term growth.
IceCure Medical Earnings release: Q2 2026
IceCure Medical released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("...
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Ho...
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroy...
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
The petition by The Society of Interventional Oncology (SIO) includes adding criteria for patients aged 50-69 who are poor surgical candidates or who decline surgery in the National Comprehensive Canc...
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CA...
IceCure Medical expands U.S. commercial team for ProSense cryoablation
IceCure Medical (ICCM) announced the expansion of its United States sales and marketing teams. In response to demand from leading hospitals and physicians across the country, the company has strengthe...
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation ...
IceCure Medical Slides: Investor presentation
IceCure Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
IceCure Medical highlights expanding commercial adoption of ProSense
IceCure Medical (ICCM) highlighted the growing international interest in its ProSense system in Brazil at the Simposio de Radiologia Intervencionista em Oncologia. “IceCure’s ProSense(TM) holds Agenci...
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer ...